HYDERABAD: Generic pharmaceuticals maker MSN Group on Thursday announced the rollout of the cheapest Covid-19 treatment drug Favipiravir 200 mg at Rs 33 per tablet under the Favilow brand.
Jenburkt Pharmaceuticals’ Favivent was hitherto the cheapest Favipiravir 200mg offering in the market at Rs 39 per tablet. While Glenmark’s Favipriavir offering Fabiflu was launched at Rs 103 per tablet and later reduced to Rs 75 per tablet, Cipla’s Ciplenza costs Rs 68, Hetero Labs’ Favivir and Brinton Pharma’s Faviton are priced at Rs 59.
Coronavirus outbreak: Live updates
The Hyderabad-based company said it is also gearing up to launch Favipiravir 400mg in the market soon. The active pharmaceutical ingredient (API) and the formulation for Favilow was developed in-house by its R&D team.
Terming Favilow as an effective and affordable Covid-19 drug, MSN Group CMD Dr MSN Reddy said: “We as a company always believe that quality medicine has to be accessible and available to everyone.”
Favipiravir has been approved by the Drug Controller General of India (DCGI) for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children suffering from mild to moderate Covid-19 symptoms.
More on Covid-19
Jenburkt Pharmaceuticals’ Favivent was hitherto the cheapest Favipiravir 200mg offering in the market at Rs 39 per tablet. While Glenmark’s Favipriavir offering Fabiflu was launched at Rs 103 per tablet and later reduced to Rs 75 per tablet, Cipla’s Ciplenza costs Rs 68, Hetero Labs’ Favivir and Brinton Pharma’s Faviton are priced at Rs 59.
Coronavirus outbreak: Live updates
The Hyderabad-based company said it is also gearing up to launch Favipiravir 400mg in the market soon. The active pharmaceutical ingredient (API) and the formulation for Favilow was developed in-house by its R&D team.
Terming Favilow as an effective and affordable Covid-19 drug, MSN Group CMD Dr MSN Reddy said: “We as a company always believe that quality medicine has to be accessible and available to everyone.”
Favipiravir has been approved by the Drug Controller General of India (DCGI) for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children suffering from mild to moderate Covid-19 symptoms.
More on Covid-19
As part of its Covid-19 treatment range, MSN has already launched anti-viral drug Oseltamivir in 75 mg capsules under the Oselow brand.
